T1	intervention 0 11	Rivaroxaban
T2	location 1296 1298	UK
T3	No-of-participants 1389 1391	88
T4	eligibility 1392 1436	treatment-na√Øve early breast cancer patients
T5	control 1500 1512	no treatment
T6	outcome-Measure 1711 1732	change in tumour Ki67
T7	outcome-Measure 1769 1916	tumour markers of apoptosis and angiogenesis, extrinsic clotting pathway activation and systemic markers of metastasis, tumour load and coagulation
